Resonance Health Ltd · ASX:RHT
Resonance Health — Investor Presentation (April 2014)
27 slides from Resonance Health's investor presentation, Apr 10, 2014
Slide 1: Resonance Health Limited Corporate Presentation
Resonance For personal use only Health Limited CORPORATE PRESENTATION April 2014 | ASX: RHT
Slide 2: Disclaimer
Disclaimer For personal use only This presentation has been prepared by Resonance Health Limited only and may contain forward-looking statements that are based on management’s current expectations and beliefs and are subject to a number of factors and uncertainties that could cause actual results to
Slide 3: Resonance Health Ltd (RHT)
Resonance Health Ltd (RHT) For personal use only ASX Listed, HQ in Perth – staff of 13 Market Capitalisation ~ $22m (360m shares on issue) • Cash on hand $750k (31 December 2013) • Cash on hand ~$850k (31 March 2014) • Inventors, Board and Management own 27.6% RHT develops and utilises patented magn
Slide 4: Snap Shot
Snap Shot For personal use only RHT established to commercialise FerriScan® • MRI based test to measure iron overload • FDA approved • FerriScan® is reimbursed in parts of the US, Canada and UK • Used by 7 of the top 10 pediatric hospitals in the US • Cash flow positive business unit, strong YOY gro
Slide 5: Liver disease is a large target market
Liver disease is a large target market For personal use only Chronic liver disease progressively destroys the liver tissue leading to liver fibrosis and cirrhosis Movements in mortality 1971-2008 Deaths per million of population Liver disease is the only major cause of death still increasing year on
Slide 6: Liver Biopsy
Liver Biopsy For personal use only GOLD STANDARD Invasive Diagnostic Method for Iron Assessment, Fatty Liver and Liver Fibrosis. Biopsy sample is 1/50,000th of the liver mass causing sampling errors that can leave the diagnosis in doubt. Major complications: Significant Pain 1:10 Bleeding 1:100 Bile
Slide 7: Growth through R&D and collaborations
Growth through R&D and collaborations For personal use only Proof of Reimbursement Research Validate U.S. 510(k) On Market concept FerriScan® (liver iron assessment) Cardiac T2* (cardiac iron assessment complements FerriScan® HepaFat Scan® (liver fat test) Liver Fibrosis Test | R&D Phase RESONANCE H
Slide 8: FerriScan
FerriScan® For personal use only Measurement of liver iron concentration using MR IMAGES
Slide 9: Iron Overload
Iron Overload For personal use only The liver is the body’s primary site for iron storage Consequences of Iron Overload Two primary causes of Iron Overload: 1. Excess dietary absorption of iron • Impaired growth and deformities • Hereditary Hemochromatosis • Liver fibrosis and cirrhosis • Venesectio
Slide 10: Causes of Iron Overload
Causes of Iron Overload For personal use only Anaemias and blood disorders Primary Iron Overload requiring repeat blood transfusions Hereditary Haemochromatosis • Inherited iron overload disorder • HH is the most common genetic disorder in Thalassaemia western populations affecting 1 in 250 people f
Slide 11: Global Access to FerriScan
Global Access to FerriScan® For personal use only Some FerriScan® locations, 250+ have been activated
Slide 12: Business Model
Business Model For personal use only HOW THE FERRISCAN SERVICE WORKS MRI images transmitted securely to FerriScan Analysis Centre Patient scanned at MRI FerriScan analysis Centre with standard process applied to MRI scanner (GE, images received Siemens or Philips) (standardized procedures and ISO ce
Slide 13: FerriScan Growth
FerriScan® Growth For personal use only Annual Image Analysis Volumes 5500 5000 4500 Double 4000 digit annual growth in 3500 volumes 3000 2500 2000 1500 2008-9 2009-10 2010-11 2011-12 2012-13 2013-14 (EST) • Revenue earned from: • the use of FerriScan® in clinical trials • sale of FerriScan® coupons
Slide 14: HepaFat-Scan
HepaFat-Scan® For personal use only Measurement of fat in the liver using MR IMAGES
Slide 15: Fatty liver market
Fatty liver market For personal use only 2/3 of American adults and 1/3 of American children are overweight. Approximately 30% of US population (~106 million) has fatty liver disease. NAFLD (non-alcoholic fatty liver disease) is the most common cause of liver disease in the western world. NAFLD is p
Slide 16: Non-alcoholic Fatty Liver Disease
Non-alcoholic Fatty Liver Disease For personal use only Fatty Fibrosis & Liver Obesity Liver Inflammation Cirrhosis Cancer 30-90% 10-20% 3-5% in ?% 20 years If left untreated, fatty liver can lead to liver inflammation, fibrosis and cirrhosis. Fatty liver disease can also lead to an increase in live
Slide 17: HepaFat-Scan Advantages
HepaFat-Scan® Advantages For personal use only • Measures the % of liver tissue containing fat which is directly equivalent to the biopsy measurement • HepaFat-Scan® can be used as a surrogate for liver biopsy measurements of liver fat • Ease to implemented, uses standard MRI scanners • Quick 3 minu
Slide 18: HepaFat-Scan Competitive Positioning
HepaFat-Scan® Competitive Positioning For personal use only Ultrasound Liver Biopsy Often used to diagnose fatty liver Measure the % of liver tissue cells containing fat Qualitative assessment of liver fat based on visual assessment Study¹ comparing the consistency of pathologists measurements found
Slide 19: HepaFat-Scan Market
HepaFat-Scan® Market For personal use only Early diagnosis of fatty liver disease and monitoring of progress US market assessment is in progress to identify initial clinical targets and go-to-market models • 106m people in the US have fatty liver disease • Assume a fee of $130 / test* • If 1% have a
Slide 20: HepaFat-Scan Market: Pharmaceutical Companies
HepaFat-Scan® Market For personal use only Pharmaceutical Companies Need an accurate non-invasive FDA approved tool to measure liver fat in their clinical trials Resonance Health has strong credentials proving imaging core lab services to pharmaceutical companies for 10+ years 246 trials currently r
Slide 21: Liver Fibrosis
Liver Fibrosis For personal use only Measurement of liver fibrosis using MR IMAGES
Slide 22: Liver Fibrosis Measurement with MRI
Liver Fibrosis Measurement with MRI For personal use only Non-invasive measurement of liver fibrosis is a large addressable market Primary causes of liver fibrosis: • Viral hepatitis – 170m people world wide have Hep C (2.7m in US) • Fatty liver disease –1/3 of American adults have fatty liver • Iro
Slide 23: Liver Fibrosis Diagnostic Tool - Status
Liver Fibrosis Diagnostic Tool - Status For personal use only Resonance Health completed a clinical study in 2012 to develop an MRI test to detect and score liver fibrosis in collaboration with Pfizer and the Victorian Liver Transplant Unit Results were equivocal Work has continued to refine the met
Slide 24: Other Opportunities
Other Opportunities For personal use only Another opportunity is currently being investigated: • MRI related technology • Due Diligence in progress • Non-Disclosure agreement prevents further disclosure at this time Continue to look for other opportunities to expand the revenue base of the Company a
Slide 25: Summary
Summary For personal use only Profitable FerriScan® Business Unit • Strong growth in FerriScan® sales volumes • Significant increase in number of FerriScan® sites activated • Expansion into new geographies • Strategic partnerships with large pharmaceutical companies FDA approval for HepaFat-Scan® Q4
Slide 26: Financial Results
Financial Results For personal use only 360m shares on issue Last capital raising in 2006 Receipts from customers in FY 2012-13 of AU$1.9m, up 34% from previous year Cash balance at 31 December 2013 AU$745k Cash balance at 31 March 2014 estimate AU$850k No debt
Slide 27: For personal use only
For personal use only
Resonance Health — Investor Presentation (April 2014) on 6ix